Maricann Group Inc (CNQX: MARI), the NA sector company, has received a rating update from a Wall Street analyst today. Analyst Neil Maruoka from Canaccord Genuity reiterated a Buy rating, with a C$4.25 price target.

According to TipRanks.com, Maruoka is ranked #533 out of 4815 analysts.

Read also: Wedbush Reaffirms Their Sell Rating on Best Buy Co

Maricann Group Inc has an analyst consensus of Hold.

Based on Maricann Group Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of C$11.43 million. In comparison, last year the company had a GAAP net loss of C$30.64K.

Maricann Group, Inc. engages in the distribution of marijuana for medical purposes. It offers a variety of oil and flower products. It operates a medical cannabis cultivation, extraction, and formulation business under federal license from the Government of Canada. The company was founded by Danny Weiss in 2013 and is headquartered in Burlington, Canada.